Peipert, J. D., Kulasekararaj, A. G., Gaya, A., Langemeijer, S. M. C., Yount, S., Gonzalez-Fernandez, F. A., . . . Kaiser, K. (2020). Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One.
Style de citation ChicagoPeipert, John Devin, et al. "Patient Preferences and Quality of Life Implications of Ravulizumab (every 8 Weeks) and Eculizumab (every 2 Weeks) for the Treatment of Paroxysmal Nocturnal Hemoglobinuria." PLoS One 2020.
Style de citation MLAPeipert, John Devin, et al. "Patient Preferences and Quality of Life Implications of Ravulizumab (every 8 Weeks) and Eculizumab (every 2 Weeks) for the Treatment of Paroxysmal Nocturnal Hemoglobinuria." PLoS One 2020.